Clinical Trial Update: Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of busulfan and fludarabine conditioning before donor stem cell transplant for hematologic cancers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• Plasma Cell Neoplasms

Drugs mentioned

• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Anemia, Chronic Myeloproliferative Disorders | Phase 2 | Status: WITHDRAWN